Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.17 USD | -3.97% | -9.83% | +2.29% |
May. 13 | Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating | MT |
May. 10 | Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 44.75M | Capitalization | 1.56B |
---|---|---|---|---|---|
Net income 2024 * | -96M | Net income 2025 * | -61M | EV / Sales 2024 * | - |
Net cash position 2024 * | 238M | Net cash position 2025 * | 151M | EV / Sales 2025 * | 31.5 x |
P/E ratio 2024 * |
-16.9
x | P/E ratio 2025 * |
-27.4
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.86% |
Latest transcript on Soleno Therapeutics, Inc.
1 day | -1.29% | ||
1 week | -7.21% | ||
Current month | -5.13% | ||
1 month | +5.56% | ||
3 months | -13.53% | ||
6 months | +46.76% | ||
Current year | +5.27% |
Managers | Title | Age | Since |
---|---|---|---|
Anish Bhatnagar
CEO | Chief Executive Officer | 56 | 05-12-31 |
James Mackaness
DFI | Director of Finance/CFO | 60 | 19-11-13 |
Ernest Mario
CHM | Chairman | 85 | 07-08-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ernest Mario
CHM | Chairman | 85 | 07-08-02 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 19-04-25 |
Bill Harris
BRD | Director/Board Member | 65 | 14-06-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 41.17 | -3.97% | 468 811 |
24-05-22 | 42.87 | -3.16% | 376,792 |
24-05-21 | 44.27 | -5.83% | 317,073 |
24-05-20 | 47.01 | +1.84% | 285,422 |
24-05-17 | 46.16 | +1.10% | 334,444 |
Delayed Quote Nasdaq, May 23, 2024 at 10:20 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.27% | 1.56B | |
+10.63% | 115B | |
+12.26% | 106B | |
-5.59% | 24.69B | |
-1.60% | 21.97B | |
-5.24% | 19.27B | |
-11.04% | 17.56B | |
-39.36% | 17.32B | |
+5.91% | 14.03B | |
+33.49% | 12.13B |
- Stock Market
- Equities
- SLNO Stock